Aethlon Medical Inc

    • Market Cap $4.06M
    • PE -0
    • Debt $NaN
    • Cash $6.95M
    • EV $NaN
    • FCF -$8.92M

    Earnings

    loading chart...

    Sales & Net Margins

    loading chart...
    Earnings-$11.27M
    EBIT-$11.57M
    ROE-187%
    ROA-131%
    FCF-$8.92M
    Equity$6.02M
    Growth Stability1
    PE-0.36
    PB0.67
    P/FCF-0.45
    Price/Cash1.71
    Sales CAGR-2%
    Equity CAGR37%
    Earnings Growth YoY-7%
    Earnings Growth QoQ9%
    Sales CAGR 5Y-11%
    Equity CAGR 5Y-6%
    Earnings CAGR 3Y-5%
    Sales CAGR 3Y-5%
    Equity CAGR 3Y-37%
    Market Cap$4.06M
    Assets$8.85M
    Cash$6.95M
    Shares Outstanding10.72M
    Working Capital4.81M
    Current Ratio3.06
    Shares Growth 3y33%
    Equity Growth QoQ-31%
    Equity Growth YoY-42%

    Assets & ROA

    loading chart...

    Stockholders Equity & ROE

    loading chart...
    Aethlon Medical Inc is a medical technology company. It is focused on addressing unmet needs in health and biodefense. The company operates through two segments namely Aethlon for therapeutic applications, which represents its therapeutic business activities and ESI for diagnostic applications which signifies diagnostic business activities. It is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and to eliminate life-threatening viruses from the circulatory system. The company generates revenue from Aethlon segment.

    SEC Filings

    Direct access to Aethlon Medical Inc (AEMD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

    • 2024
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-K Mar 31
    • 2023
      • 10-Q Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-K Mar 31
    • 2022
      • 10-Q Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-K Mar 31

    Sector Comparison

    How does Aethlon Medical Inc compare to its competitors?

    Loading chart...

    Peter Lynch's Chart

    This chart shows the current pricing of Aethlon Medical Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

    loading chart...

    Aethlon Medical Inc Discounted Cash Flow

    Fully customizable DCF calculator online for Aethlon Medical Inc.

    = -$89M
    012345678910TV
    fcf-$8.9M-$8.9M-$8.9M-$8.9M-$8.9M-$8.9M-$8.9M-$8.9M-$8.9M-$8.9M-$8.9M-$89M
    DCF-$8.1M-$7.4M-$6.7M-$6.1M-$5.5M-$5M-$4.6M-$4.2M-$3.8M-$3.4M-$34M
    Value-$89M

    Competitiveness and MOAT

    High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

    Years03/201503/201603/201703/201803/201903/202003/202103/202203/202303/2024TTM
    Net Margins-915%-559%-2K%-4K%-3K%-981%-1K%-4K%-2K%--
    ROA--171%-353%-66%-146%-57%-74%-54%-68%-153%-131%
    ROE--319%-1K%-93%-256%-68%-84%-61%-80%-212%-187%

    Safety and Stability

    Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

    Years03/201503/201603/201703/201803/201903/202003/202103/202203/202303/2024TTM
    Debt over FCF--0.12-0.15-0.47-0.22-0-----
    Debt over Equity0.240.340.770.30.40-----
    Growth Stability----------1

    Growth

    Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

    Years03/201503/201603/201703/201803/201903/202003/202103/202203/202303/2024CAGR 5Y
    Revenue YoY growth-16%-56%-62%53%183%1%-55%95%-100%-11%
    Earnings YoY growth--29%47%-22%9%3%24%32%15%1%-
    Equity YoY growth-138%-56%807%-60%288%0%82%-12%-62%-6%
    FCF YoY growth--14%-19%12%9%25%28%48%13%-9%-